|
Atlas Antibodies
rabbit anti mef2c polyclonal ![]() Rabbit Anti Mef2c Polyclonal, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit anti mef2c polyclonal/product/Atlas Antibodies Average 93 stars, based on 1 article reviews
rabbit anti mef2c polyclonal - by Bioz Stars,
2026-03
93/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
rabbit polyclonal anti mef2c ![]() Rabbit Polyclonal Anti Mef2c, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit polyclonal anti mef2c/product/Cell Signaling Technology Inc Average 95 stars, based on 1 article reviews
rabbit polyclonal anti mef2c - by Bioz Stars,
2026-03
95/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
rabbit polyclonal anti-mef2c ![]() Rabbit Polyclonal Anti Mef2c, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit polyclonal anti-mef2c/product/Santa Cruz Biotechnology Average 90 stars, based on 1 article reviews
rabbit polyclonal anti-mef2c - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Thermo Fisher
rabbit polyclonal igg anti-mef2c ![]() Rabbit Polyclonal Igg Anti Mef2c, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit polyclonal igg anti-mef2c/product/Thermo Fisher Average 90 stars, based on 1 article reviews
rabbit polyclonal igg anti-mef2c - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
polyclonal antibodies against mef2c ![]() Polyclonal Antibodies Against Mef2c, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/polyclonal antibodies against mef2c/product/Cell Signaling Technology Inc Average 95 stars, based on 1 article reviews
polyclonal antibodies against mef2c - by Bioz Stars,
2026-03
95/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
rabbit polyclonal anti mef2c sc313 ![]() Rabbit Polyclonal Anti Mef2c Sc313, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit polyclonal anti mef2c sc313/product/Santa Cruz Biotechnology Average 90 stars, based on 1 article reviews
rabbit polyclonal anti mef2c sc313 - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
ABclonal Biotechnology
rabbit polyclonal anti-mef2c antibody ![]() Rabbit Polyclonal Anti Mef2c Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rabbit polyclonal anti-mef2c antibody/product/ABclonal Biotechnology Average 90 stars, based on 1 article reviews
rabbit polyclonal anti-mef2c antibody - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
Journal: bioRxiv
Article Title: Heterochronic transcription factor expression drives cone-dominant retina development in 13-lined ground squirrels
doi: 10.1101/2025.04.25.650540
Figure Lengend Snippet: Mef2c is sufficient to promote cone-specific gene expression and repress rod-specific gene expression in mouse. ( A ) Diagram of overexpression strategy used to test effects of MEF2C overexpression. ( B ) UMAP representation of P8 mouse retinal explants electroporated with a plasmid expressing GFP alone (Empty) or GFP in a bicistronic transcript with human MEF2C ( MEF2C ), (n = 7445 cell Empty, 11949 cells MEF2C ). Each point represents a single cell and is colored by cell type as determined by clustering and marker gene expression. ( C ) Heatmap of expression for select genes for cones, cone-like photoreceptor precursors, rod photoreceptor precursors, and rods in cells overexpressing MEF2C , scaled by gene. ( D ) Immunohistochemistry showing GFP and GNAT2 expression in P8 mouse retinas from Empty and MEF2C conditions. Scale bars, 50 µm. ( E ) Box plot of the number of Gnat2+, GFP+ cells divided by the total number of GFP+ cells (n = 8 for both conditions). P-values calculated by Wilcoxon rank-sum test. P0, postnatal day 0; P8, postnatal day 8; FACS, fluorescence-activated cell sorting; scRNA-Seq, single-cell RNA sequencing; ONL, outer nuclear layer; INL, inner nuclear layer; DAPI, 4′,6-diamidino-2-phenylindole; GFP, green fluorescent protein; OE, overexpression.
Article Snippet: Primary antibodies utilized for staining 13LGS sections included goat anti-Otx2 polyclonal IgG (R&D Systems, BAF1979, 1:400) and
Techniques: Gene Expression, Over Expression, Plasmid Preparation, Expressing, Marker, Immunohistochemistry, Fluorescence, FACS, RNA Sequencing
Journal: medRxiv
Article Title: Biallelic PAX7 variants cause a novel Satellite Cell-opathy with progressive muscle involvement resembling facioscapulohumeral muscular dystrophy
doi: 10.1101/2025.03.03.25322917
Figure Lengend Snippet: A. Representative images of immunolabelling for PAX7 (red) counterstained with Wheat Germ Agglutinin (WGA, white) and Hoechst (blue) showing satellite cells, fibre boundaries and nuclei respectively in different biopsies (CTRL: healthy; NAM: Necrotising Autoimmune Myopathy; FSHD STIR +ve : active; and FSHD STIR -ve : non-active disease). Percentage of PAX7 +ve nuclei (satellite cells) over the total nuclei in the section is reported per each biopsy. Green arrowheads indicate satellite cells, with representative images shown in insets. B. Schematic of retroviral infection to obtain stable cell lines, encoding for either PAX7 wild-type (PAX7wt) or PAX7 P112L-C443Y (PAX7mut), and GFP alone (empty vector; EV). RT-qPCR confirming increased PAX7 expression in both PAX7wt and PAX7 mut cell lines compared to empty vector control cells. C. Representative images of proliferating EV, PAX7wt or PAX7mut myoblast lines immunolabelled for GFP (green), PAX7 (red) and nuclei counterstained with Hoechst (white), showing clear accumulation of PAX7 in PAX7wt or PAX7mut cells. D. Quantification of PAX7 nuclear staining confirms similar accumulation and nuclear localisation in both PAX7wt or PAX7mut cell lines. E. Schematic of experimental design for differentiation analysis. Myoblasts were plated at equal numbers and induced to differentiate for 2 days, prior to immunolabelling. Representative images of myotubes from EV, PAX7wt or PAX7mut differentiated myoblasts immunolabelled for MyHC (red), GFP (green), MEF2C (magenta) and nuclei counterstained with Hoechst (white), showing severely reduced myotube formation in PAX7wt compared to PAX7mut and EV control cells. F. Example of thresholded images from E used for quantification of MyHC labelling. MyHC +ve area is dramatically reduced in PAX7wt differentiated cells, but not in PAX7mut compared to EV control. G. PAX7wt or PAX7mut myoblasts differentiate in myotube with significantly reduced diameter myotubes compared to EV control. All graphs report unpaired t-test analysis.
Article Snippet: Primary antibodies were: mouse monoclonal anti-PAX7 (Developmental Studies Hybridoma Bank; 1:500), chicken polyclonal anti-GFP (Abcam; ab13970; 1:1000), mouse monoclonal anti-MyHC (Developmental Studies Hybridoma Bank; MF20; 1:400) and
Techniques: Retroviral, Infection, Stable Transfection, Plasmid Preparation, Quantitative RT-PCR, Expressing, Control, Staining
Journal: Journal of translational medicine
Article Title: The spatiotemporal matching pattern of Ezrin/Periaxin involved in myoblast differentiation and fusion and Charcot-Marie-Tooth disease-associated muscle atrophy.
doi: 10.1186/s12967-023-04016-7
Figure Lengend Snippet: Fig. 3 Ezrin was involved in myoblast differentiation/fusio. A Typical image of MyHC staining in differentiated C2C12 myoblasts treated with Ezrin overexpression or knockdown for 2, 4 and 6 days. B–D A quantitative assay for the number of MyHC + myotubes with more than 5 nuclei was performed 2, 4 and 6 days after myoblast differentiation after overexpression or knockdown of Ezrin. Three independent experiments were performed, n = 3, *P < 0.05 vs. Ad-Null; #P < 0.05 vs. Ad-Null. E RNA-seq analysis of myoblast differentiation in C2C12 myoblasts with overexpression or knockdown of Ezrin at 6 days. n = 3. F–I MyoG and MEF2c fluorescence staining and quantitative assay for myoblast differentiation. Red fluorescence indicates MyoG or MEF2c; DAPI indicates the nucleus. Three independent experiments were performed, n = 3, *P < 0.05 vs. Ad-Null; #P < 0.05 vs. Ad-Null
Article Snippet: Primary monoclonal and
Techniques: Staining, Over Expression, Knockdown, RNA Sequencing, Fluorescence
Journal: Journal of translational medicine
Article Title: The spatiotemporal matching pattern of Ezrin/Periaxin involved in myoblast differentiation and fusion and Charcot-Marie-Tooth disease-associated muscle atrophy.
doi: 10.1186/s12967-023-04016-7
Figure Lengend Snippet: Fig. 7 NFAT signaling is involved in the regulation of myoblast differentiation/fusion mediated by Ezrin. A RNA-seq analysis of the CaN-NFAT signaling pathway in C2C12 myoblasts with overexpression or knockdown of Ezrin at 6 days. n = 3. B Western blot of NFATc1-c4 proteins in myoblasts treated with Ezrin overexpression or knockdown for 6 days. C–F Quantitative analysis of NFATc1-c4 protein expression was performed 6 days after myoblast differentiation following Ezrin overexpression or knockdown. Three independent experiments were performed, n = 3, *P < 0.05 vs. Ad-Null; #P < 0.05 vs. Ad-Null. G Typical image of MyHC, MyoG or MEF2c staining in differentiated C2C12 myoblasts treated with Ad-shEzrin with or without Ad-NFATc1, Ad-NFATc2, Ad-shNFATc3 and Ad-shNFATc4. Red fluorescence indicates MyHC, MyoG or MEF2c; DAPI indicates the nucleus. H–J Quantitative assay for MyHC + myotubes and MEF2c + or MyoG + nuclei numbers in the above images. Three independent experiments were performed, n = 3, *P < 0.05 vs. Ad-Null; #P < 0.05 vs. Ad-shEzrin; &P < 0.05 vs. Ad-shEzrin; $P < 0.05 vs. Ad-shEzrin
Article Snippet: Primary monoclonal and
Techniques: RNA Sequencing, Over Expression, Knockdown, Western Blot, Expressing, Staining, Fluorescence
Journal: Journal of translational medicine
Article Title: The spatiotemporal matching pattern of Ezrin/Periaxin involved in myoblast differentiation and fusion and Charcot-Marie-Tooth disease-associated muscle atrophy.
doi: 10.1186/s12967-023-04016-7
Figure Lengend Snippet: Fig. 9 Working Model: The spatiotemporal matching pattern of Ezrin/Periaxin was involved in muscle repair in a peroneal nerve injury model. Instantaneous L-periaxin expression was highest on the 6th day, while Ezrin expression peaked on the 4th day during myoblast differentiation/ fusion (A). Ezrin promoted myoblast differentiation/fusion, myotube length and size, and myofiber specialization. L-periaxin acted as a brake for myotube length and size, negatively regulating the effect of Ezrin on myotube formation (A, B). The effects of Ezrin were related to the activated PKA-NFAT-MyoD/MEF2C signaling pathway (C). Combined gene therapy with Ezrin and L-periaxin contributed to muscle repair in a peroneal nerve injury model (D), providing a novel therapeutic strategy for the treatment of nerve injury, especially CMT4F-associated muscle atrophy
Article Snippet: Primary monoclonal and
Techniques: Expressing